Insurance · Deep dive

Indigo

An AI-driven medical malpractice startup writing out of a South Carolina risk retention group — Vertical AI on top of physician risk data, with barely two years of loss experience underneath it.

emerging

The question that decides it: Can Indigo's loss experience actually hold up once its 2023-2024 policies clear the two-to-four-year MPL claim tail, or does the AI-underwriting advantage evaporate the way telematics-led Lemonade's did in personal auto once real severity showed up? The answer is binary and it lands in 2027-2028.

My take ★★ Very interesting ★ Interesting − Maybe ✗ Not interesting

Snapshot

Indigo is a Miami-based, AI-first medical professional liability (MPL) insurer that writes physicians and small medical groups through a Charleston, SC risk retention group and distributes through independent brokers. Founded in 2023 by former OppFi and Cadre CEO Jared Kaplan alongside Matt Kim of healthcare incubator Rubicon Founders, it launched coverage in Illinois, Ohio, and Washington in October 2023 and has since expanded across a growing state footprint. In January 2026 it raised an oversubscribed $50M Series B led by Rubicon Founders with new investor Town Hall Ventures joining Oak HC/FT and Optum Ventures, on the back of nearly 1,000 insured providers and more than $10M of written premium (Business Wire, Jan 2026). Its proprietary underwriting model — branded Lux — automatically underwrote 20% of submissions by year-end 2025 (Business Wire, Nov 2025). The company is real, growing, and — critically — young enough that no one, including its underwriters, yet knows how the book will actually pay.

Founding story

Kaplan came to Indigo from three prior operator seats that map into it. At Accretive, the Chicago investment firm, he co-founded Insureon, an online small-business P&C agency later sold to Hub International and Bold Penguin — his insurance-distribution credential. He then ran OppFi (NYSE: OPFI), an AI-driven consumer lender that reached the public markets via SPAC in 2021, and served as CEO of commercial-real-estate marketplace Cadre. Three chapters, one thesis: apply a modern data stack to a manually underwritten financial product.

Kim is the healthcare-and-capital other half. Rubicon Founders, based in Nashville, does not just invest — it incubates. Kim joined in 2021 and has co-founded multiple Rubicon portfolio companies; Indigo is one of them. That co-founding structure explains why Rubicon leads every Indigo round and why healthcare-native funds Optum Ventures and Oak HC/FT were in from launch. Whelan-led Town Hall Ventures joined the 2026 B.

The pitch was straightforward: MPL is a $9-10B specialist line dominated by physician-owned mutuals that are structurally slow, distribution-locked, and analytically thin — MedPro’s balance sheet excepted. A purpose-built model trained on the data points that describe an individual physician’s practice could, the thesis went, price cleaner risks faster and cheaper than the mutuals, and use the ease-of-doing-business win to pull brokers over.

How it works

The plumbing under Indigo is more traditional than the AI marketing implies. Indigo Inc. writes policies through Indigo Risk Retention Group Inc. (NAIC No. 17484), domiciled in Charleston, SC, and rated A- (Excellent) by AM Best. A risk retention group is a federal-preemption vehicle created under the Liability Risk Retention Act of 1986: policyholders — here, physicians — are also the owners of the insured pool, and the RRG can write commercial liability nationwide without being separately admitted in each state, provided every insured joins the group. That structure is why Indigo could go from launch to a nationwide footprint in roughly two years without waiting on 50 state carrier licenses.

The intelligence sits above the paper. Lux, Indigo’s proprietary underwriting platform, ingests structured data on a physician submission — NPI number, board certification, specialty, procedure mix, historical claims and paid-loss detail, National Practitioner Data Bank (NPDB) history, state board actions, entity structure, prior carrier information — and scores it against Indigo’s risk model. A submission that clears model thresholds is quoted and bound with no human underwriter in the loop; anything on the edges routes to one of five underwriters (Business Wire, Nov 2025). That five-person underwriting team is on pace to touch more than 7,000 submissions in 2025 — a throughput ratio that would take an incumbent mutual four to five times the headcount to match.

Because the RRG owns the paper, losses land on the RRG’s surplus, not Indigo Inc. But Indigo Inc. is not risk-free: RRG surplus is capital the operating company must keep replenishing to grow, and any capital-consuming loss flows straight into how much premium Indigo can write next year. Reinsurance panel members are undisclosed — a gap a serious investor would want to close.

Product and business overview

Indigo sells a claims-made MPL policy to physicians and small medical groups across essentially all specialties — specialty landing pages cover family medicine, internal medicine, OB/GYN, surgery, anesthesiology, radiology, emergency medicine, dermatology, psychiatry, and preventive medicine among others. The core is a standard-form claims-made policy with prior acts and tail options; the differentiated wrappers are the pieces Indigo has layered on since launch:

• Expert Witness Liability Coverage (May 2025) — extends professional liability protection to the physician’s activity as an expert witness, an exposure most incumbent forms exclude or silently omit.
• Broker Portal (June 2025) — the distribution-side product: real-time submission status, policy documents, and book-of-business analytics for the appointed broker.
• AI-driven quoting — the top-of-funnel speed pitch, marketed as materially faster than the legacy multi-week underwriting cycle.

Indigo does not (as of 2026) publish a hospital / large-system form; that is a different animal, requires much larger balance-sheet capacity, and would put it directly against MedPro and TDC. The stated wedge is the solo and small-group practitioner — a large but fragmented segment where distribution economics reward automation.

Business model and pricing

Indigo earns premium into the RRG and pays claims out of it. It does not disclose a fronting-and-cede structure, so the working assumption is that the RRG retains a meaningful net position and cedes the excess layers to a reinsurance panel; that panel is undisclosed. Operating-company economics resemble a managing general underwriter’s — Indigo bills the RRG for underwriting, distribution, and claims services — but the entity relationships are collapsed enough that the P&L should be read as one book.

On price: Indigo’s own marketing claims premium reductions of “10% or more” versus a physician’s prior carrier. There is no published rate card — MPL never has one — and premiums range from a few thousand a year for a low-risk family-medicine physician in a favorable state to well into six figures for an obstetrician or neurosurgeon in a plaintiff-friendly jurisdiction. The 10%+ savings claim is exactly what a challenger MPL always says, and exactly what a mutual will call the sound of adverse selection.

Traction over time

Two caveats matter. First, “premium >$10M” and “~1,000 providers” are the January 2026 disclosed data points, up from launch just 27 months earlier; on a raw run-rate basis this is a fast start for a specialty commercial line where distribution is broker-mediated and closing cycles are long. Second, none of these numbers say anything about loss experience. MPL is a long-tail line: a claim reported today can develop, litigate, and pay out three to seven years later. Indigo’s oldest policies were bound in late 2023. The book has not yet seen its own tail.

Market analysis

The US medical professional liability market is roughly $9.4B in direct premiums written for specialist MPL insurers in 2025, up 3.6% year over year (Best’s Market Segment Report / Agency Checklists, 2025). Including diversified writers, total direct premium is closer to $12B. The top five groups control more than 44% of the market. Berkshire Hathaway’s MedPro alone was $2.2B DWP / 17.72% share in 2025; The Doctors Company (post-ProAssurance close, June 2026) is now the clear #2 at $2.5B+ DWP and roughly 200,000+ insured professionals.

The structural forces are not investor-friendly. Nuclear verdicts are the story of the decade in MPL: 70 med-mal verdicts exceeded $10M in 2023, 52 in 2024, and 60 in 2025 (verdict-tracker data cited via Claims Journal, Oct 2025). The average of the top 50 verdicts jumped from $32M in 2022 to $48M in 2023 to $56M in 2024. In 2025, a Utah birth-injury case produced a $951M award, reportedly the largest MPL verdict in US history. NAIC actuarial-opinion filings for year-end 2025 saw more than 60% of the top MPL writers flag social inflation as a material-adverse-deviation risk. Physician premiums have risen for seven straight years across at least 36 states (2025).

Competitive intel

The sidebar carries the scaled list. The strategic read: Indigo has no true AI-native peer at scale — the closest analog in an adjacent line is Cover Whale in commercial auto — and its real competitors are the physician-owned mutuals it is trying to peel brokers away from. TDC, post-ProAssurance, is now big enough to defend price and product; MedPro will not lose a physician it wants; regional mutuals MagMutual and Curi own the doctor-relationship layer Indigo has to break through a broker. A lightweight AI overlay is not, on its own, a moat — any top-five carrier could buy or build one. Indigo’s real defensibility question is whether it can compound a proprietary physician-level loss-experience dataset fast enough to matter before the incumbents copy it.

History and evolution

• 2023 — Indigo founded in Miami by Jared Kaplan and Matt Kim (Rubicon Founders). Launch financing from Rubicon Founders and Oak HC/FT, with Optum Ventures and other strategic investors.
• October 2023 — Public launch of MPL coverage in Illinois, Ohio, and Washington; Indigo Risk Retention Group Inc. becomes the writing entity (Business Insurance / Coverager, Oct 2023).
• March 2025 — Medical Liability Monitor profile reports Indigo’s “inaugural year” growth; state expansion continues.
• May 2025 — Launches Expert Witness Liability Coverage.
• June 2025 — Launches Broker Portal, formalizing the independent-broker distribution model.
• November 2025 — Announces the 20%-of-submissions AI-underwriting milestone with a five-person underwriting team on pace for 7,000+ submissions in 2025.
• January 29, 2026 — Closes oversubscribed $50M Series B led by Rubicon Founders; Town Hall Ventures joins as a new investor; Optum Ventures and existing strategic investors follow. Coverage now marketed as nationwide via the RRG structure.
• 2026 (implied) — Company signals continued state expansion, R&D investment in Lux, and broker-network build-out as the use of Series B proceeds.

The evolution is a clean line so far — but the pattern to watch is what a nuclear verdict inside the Indigo book does to it. That data point does not yet exist.

What people say

The case for. Reviews are early and positive but thin. Trustpilot carries a small set of physician reviews of getindigo.com highlighting fast, responsive service — one physician describing a lawsuit dismissed with prejudice inside two weeks after Indigo assigned counsel, another citing reasonable rates and attentive check-ins two years into the relationship. Company blog and press coverage in Medical Economics, HIT Consultant, and Business Insurance all reinforce the “faster and cheaper” story, and the January 2026 investor bench (Rubicon Founders, Town Hall Ventures, Oak HC/FT, Optum Ventures) is legitimate healthcare capital, not tourist money. The A- (Excellent) AM Best rating on the RRG is a real credential — hard to obtain, and the minimum most physician-employer contracts require.

The complaints. Criticism is thin mainly because the book is small and young — Insurance Journal and Business Insurance coverage has been descriptive rather than skeptical. But the industry-side objections write themselves. Actuary.info’s mid-2025 note on legal-liability AI endorsements — the closest analog — warned that surcharges on AI-related coverages are being set by underwriting judgment rather than actuarial data, with “substantial” initial-underpricing risk in lines that have no tail data. That warning applies directly to Indigo’s own book: a two-year-old MPL insurer’s loss ratio is largely unearned, and the AI advantage claim is unfalsifiable until claims develop. Structurally, RRGs cannot write workers’ comp and cannot easily backstop the hospital-system exposure that increasingly employs the physicians Indigo insures — a growth ceiling set by federal law, not execution. When a nuclear verdict eventually lands on Indigo’s book, the RRG surplus and an undisclosed reinsurance panel are what stand between Indigo and a capital raise. And on distribution, the “we’re the broker’s friend” pitch runs into MedPro, TDC, MagMutual and Coverys, all of which have decades of embedded broker relationships, contingent-commission programs, and physician-owner loyalty. Overturning that on 24-month sales cycles is expensive.

Outlook: the open question

The question resolves in the loss triangles, and not before 2027-2028. Indigo has done the easy part of an MPL launch: raise credible healthcare capital, obtain an A- Best rating on an RRG, ship a usable broker portal, and prove that a modern data pipeline can automate a chunk of a submission workflow that mutuals still do manually. Growing from zero to ~1,000 physicians and $10M+ in premium in 27 months on a five-person underwriting bench is genuinely good execution.

None of that answers the only question that matters. Medical malpractice is a long-tail claims-made line: incidents that occurred under a 2024 policy can be reported and litigated through 2027 or later, and severity trends today — 60 nuclear verdicts in 2025, a $951M Utah award, seven straight years of physician-premium increases across most of the country — mean each one of those late-emerging claims can be enormous. Indigo’s underwriting advantage is a hypothesis until its own loss triangles say it is a fact. If the AI-scored risks develop cleaner than the mutuals’ book at comparable rate, Indigo has a defensible franchise and a big fundraise ahead of it. If they develop worse — the Lemonade personal-auto pattern, where an insurtech’s early loss ratios looked good until actual severity showed up — the RRG has to raise rate, tighten appetite, or take capital, and the growth story unwinds fast.

Two things make this different from the auto-insurtech cautionary tales. First, physician MPL has genuinely bad incumbent data hygiene; the analytical alpha here is more real than in auto. Second, the RRG structure keeps losses inside a mutualised pool, which softens the drama for Indigo Inc. shareholders but does not make it disappear. The thing to watch is the year-end 2027 Best’s report on Indigo Risk Retention Group Inc.: policyholder surplus, loss development on the 2023-2024 accident years, and whether the reinsurance panel — undisclosed today — is re-upping capacity at flat or hardening terms. Those three data points are the answer.

How a challenger would attack it

Wait for the triangles, then hit the renewal book. Indigo’s position rests on two thin legs: a “10% or more” price promise made before any of its 2023-2024 policies have cleared the MPL claim tail, and a technology story any top-five carrier could replicate. The obvious challenger isn’t a startup — it’s MedPro or TDC bolting a Lux-equivalent onto a century of settled loss data, then matching Indigo’s quote-speed while whispering “adverse selection” to every broker Indigo has appointed. But a startup attack exists too: Indigo’s own structure is its ceiling. An RRG cannot write workers’ comp and cannot hold hospital-system exposure, so a challenger writing on admitted paper with a fronting carrier can bundle what Indigo legally cannot — covering the growing share of physicians employed by systems — and pitch brokers a fuller product. Timing is the weapon. Indigo’s reinsurance panel is undisclosed and its surplus is small; a single nuclear verdict landing in the 2027-2028 development window (60 verdicts over $10M in 2025, a $951M Utah award) forces rate increases or a capital raise, and that is the quarter a challenger floods Indigo’s brokers with takeout quotes on the clean risks Lux originally selected — the exact risks that are cheapest for anyone to underwrite once Indigo has flagged them.

Same playbook, new buyer

Run Lux-style underwriting on the professionals the mutuals ignore. Indigo’s real innovation — structured data ingestion (NPI, NPDB, board actions, procedure mix) scored by a model, five underwriters processing 7,000 submissions — is a throughput machine, and physicians are merely the first fragmented professional class it was pointed at. The same architecture ports to allied health (nurse practitioners, PAs, therapists, med-spa operators), dentists, or veterinarians: lines with public credentialing data, smaller limits, shorter tails, and no MedPro-grade incumbent sitting on a century of data. Shorter tails matter strategically — the loss-experience question that hangs over Indigo for five years resolves in two, so the model proves out faster and cheaply. A second shift is buyer structure: sell the underwriting engine to hospital systems and captives insuring their employed physicians — the segment the RRG structure locks Indigo out of by federal law. Indigo won’t follow either move soon: its capital, its A- rating, and its Rubicon-incubated thesis are all committed to winning solo/small-group physician MPL, and diversifying lines before its first accident years develop would look, to its own reinsurers, like a company hedging its founding bet.

Sources and further reading

• Business Wire — Indigo Raises $50 Million to Modernize Medical Malpractice Insurance Nationwide (Jan 29, 2026)
• Business Wire — Indigo Reaches Milestone: 20% of Submissions Now Fully Underwritten by AI (Nov 3, 2025)
• Business Wire — Indigo Launches State-of-the-Art Broker Portal (Jun 23, 2025)
• Business Wire — Indigo Expands Medical Malpractice Coverage with Expert Witness Protection (May 19, 2025)
• Business Insurance — Indigo launches AI platform for medical professional liability coverage (Oct 2023)
• Refresh Miami — Indigo raises a $50M Series B to modernize malpractice insurance (Jan 29, 2026)
• Insurance Journal — The Doctors Group Completes $1.3B Purchase of ProAssurance (Jun 29, 2026)
• Agency Checklists — NAIC 2025 Market Share Report: Top 25 Medical Professional Liability Insurers (Mar 31, 2025)
• Claims Journal — The Impact of Nuclear Verdicts on Casualty Claims (Oct 30, 2025)
• Becker’s ASC — The biggest nuclear malpractice verdicts in 2025
• Rubicon Founders — Indigo portfolio page
• BBB — Indigo Risk Retention business profile (Charleston, SC)